The Immutep (ASX:IMM) share price is up 25% in a month and could go higher

This biotech company's shares have been on fire…

| More on:
four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immutep Ltd (ASX: IMM) share price is pushing higher again on Monday despite the market decline.

At the time of writing, the biotechnology company's shares are up almost 4% to 55 cents.

This means the Immutep share price is now up 25% in the space of a month.

Why is the Immutep share price charging higher this month?

Investors have been bidding the Immutep share price higher in recent weeks following a series of positive updates.

One of those was the announcement of the grant of a patent in China in late August. This patent relates to LAG525, which is a humanised form of Immutep's IMP701 antibody which is out-licensed to Novartis.

The company followed this up a few days later with another announcement relating to its Chinese operations. The release explains that its Chinese partner for eftilagimod alpha (efti), EOC Pharma, is planning to expand its clinical trial pipeline.

EOC Pharma is preparing to initiate a clinical trial of efti in combination with an anti-PD-1 therapy. The new trial builds on the latest promising data presented by Immutep at ASCO 2021 and on previously announced Phase II trial evaluating efti in combination with chemotherapy in metastatic breast cancer patients.

And then finally, earlier this month the company revealed that the last patient has been enrolled and safely dosed in its Stage 2 of Part B of its Phase II TACTI-002 study.

This study is being conducted in collaboration with Merck & Co. It is evaluating the combination of efti with Merck's Keytruda product in up to 183 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

Immutep expects to report further data from TACTI-002 at a scientific conference in calendar year 2021 or early calendar year 2022.

Are its shares good value?

Despite the strong gain by the Immutep share price over the last few weeks, one leading broker believes it could still go higher.

According to a recent note out of Bell Potter, its analysts have a speculative buy rating and $1.00 price target on the company's shares.

Based on the current Immutep share price, this implies potential upside of 82% over the next 12 months.

It commented: "We retain Buy (spec). Our hypothetical M&A valuation for IMM is revised to $1.48/sh, which helps ground our DCF valuation. IMM remains one of our key picks in the biotech space for FY22."

Should you invest $1,000 in Immutep Limited right now?

Before you buy Immutep Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Immutep Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy finish to the week for ASX shares this Friday.

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
Share Gainers

5 ASX All Ords stocks rocketing higher this week

Investors sent these five ASX All Ords stocks soaring this week. But why?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why Boss Energy, Capstone, Dimerix, and Platinum shares are storming higher today

These shares are having a good finish to the week. Let's find out why.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was the ASX's fourth day of gains for the week today.

Read more »

a man raises his fists to the air in joyous celebration while learning some exciting good news via his computer screen in an office setting.
Share Gainers

Why Cedar Woods, Healius, NextDC, and Platinum shares are charging higher today

These shares are rising on Thursday. But why are investors buying them? Let's find out.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Share Gainers

These were the best-performing ASX 200 shares in April

These shares were in fine form in April. Let's see why they outperformed.

Read more »

Hiker man backpacker with hands up in the summer mountains with cloudy sky.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX made it three from three.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why Cedar Woods, Orthocell, PEXA, and St Barbara shares are storming higher today

These shares are having a good session on hump day. But why?

Read more »